Dr Lal PathLabs To Acquire 70% Stake In SN Genelab

DrLaL Labs has announced a ₹168 crore acquisition of a 70% stake in SN Genelab, a move that will expand the company's presence in advanced diagnostics and genomics. The Deal The acquisition will give Dr Lal PathLabs a controlling interest in SN Genelab. The transaction is expected to strengthen the company's capabilities in genomics while adding another specialised diagnostics platform to its existing business. **Why Genomics Matters** Genomic testing is becoming an increasingly important part of advanced healthcare, particularly in areas such as cancer diagnostics, inherited disorders and personalised medicine. Expanding into this segment gives diagnostic companies an opportunity to participate in higher-value testing services. **Business Context** Dr Lal PathLabs is one of India's established diagnostic services companies, operating laboratories and collection centres across the country. Its business spans pathology, preventive healthcare and specialised diagnostic testing. **Strategic Significance** The acquisition broadens the company's advanced diagnostics portfolio at a time when healthcare providers are increasingly expanding beyond conventional pathology testing. The addition of genomics capabilities could complement Dr Lal PathLabs' existing diagnostic network. What To Watch Investors will be watching the integration of SN Genelab, the contribution of genomic testing to overall revenue and whether the company pursues additional acquisitions in specialised diagnostics. This update is based on publicly reported company information. It is not investment advice.